Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab versus placebo in active psoriatic arthritis after inadequate response to anti-TNF therapy
2018-003214-41Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Guselkumab with Placebo (2 arms). Primary endpoint: American College of Rheumatology 20 response. Started Nov 2018; status: completed.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2018-003214-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003214-41.